Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents

(2020) Binbin Cheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint

(2020) Magdalena Konieczny et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of [1,2,4]Triazolo[4,3-a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction

(2019) Mingze Qin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Design, Synthesis, Evaluation, and Structural Studies of C2-Symmetric Small Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction

(2019) Subhadwip Basu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small Molecules Drive Big Improvements in Immuno-Oncology Therapies

(2018) Bayard R. Huck et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-ligand 1 Signaling Pathway

(2018) Tianyu Wang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cancer immunologists scoop medicine Nobel prize

(2018) Heidi Ledford et al.   NATURE

Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1

(2017) Katarzyna Guzik et al.   JOURNAL OF MEDICINAL CHEMISTRY

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

(2017) Lukasz Skalniak et al.   Oncotarget

Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18

(2016) Silvia Carvalho et al.   BRITISH JOURNAL OF PHARMACOLOGY

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

(2015) J. Naidoo et al.   ANNALS OF ONCOLOGY

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies

(2013) Caroline Robert et al.   EUROPEAN JOURNAL OF CANCER

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology